Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HCPCS public meetings

This article was originally published in The Gray Sheet

Executive Summary

Only one of 45 requests for new Healthcare Common Procedure Coding System Level II codes for supplies and other durable medical equipment is granted in preliminary decisions from CMS. The agency is holding a public meeting on the preliminary decisions April 122-223 in Baltimore. The lone successful request comes from CircAid Medical Products for its T-3 M gradient compression surgical dressing system. Several antimicrobial dressings are denied requests for new codes based on CMS' contention that there is no clinical evidence of their superiority to other dressings with which they are now grouped. In the separate category of orthotics and prosthetics, CMS will hold a public meeting 3May 6 to discuss preliminary decisions granting one of 12 requests for new codes (4"The Gray Sheet" April 16, 2007, p. 4)

Latest Headlines
See All
UsernamePublicRestriction

Register

MT026019

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel